Core Viewpoint - Northeast Pharmaceutical (000597.SZ) is launching a shareholder reward program to express gratitude to shareholders and enhance their understanding of the company's intrinsic value while promoting its new beauty products [1] Group 1: Shareholder Reward Program - The company is initiating a "shareholder reward activity" to thank shareholders for their long-term support [1] - The program includes a dual surprise offer for eligible shareholders, which involves downloading the "Enterprise WeChat APP" and entering a company-specific WeChat group for identity verification [1] - Shareholders can unlock a "buy 1 get 4" offer on the company's proprietary "Qifangyuan" beauty product series, along with an exclusive 10% discount [1] Group 2: Promotional Details - The dual benefits are available from December 25, 2025, to December 28, 2025, exclusively on the company's authorized online store [1] - Each order is limited to one 10% discount coupon, which cannot be exchanged for cash or combined with other non-shareholder exclusive offers [1] - The discount coupon will automatically expire if not used within the specified period [1]

海南海药今日涨停，全天换手率29.43%，成交额29.66亿元，振幅4.29%。龙虎榜数据显示，机构净买入 1.28亿元，深股通净买入1.30亿元，营业部席位合计净卖出1672.42万元。 深交所公开信息显示，当日该股因日涨幅偏离值达10.02%上榜，机构专用席位净买入1.28亿元，深股通 净买入1.30亿元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交6.90亿元，其中，买入成交额为4.65亿 元，卖出成交额为2.25亿元，合计净买入2.41亿元。 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 深股通专用 | 19529.33 | 6564.83 | | 买二 | 机构专用 | 7509.36 | 4758.72 | | 买三 | 机构专用 | 7268.61 | 1843.52 | | 买四 | 国盛证券有限责任公司上海浦东新区世纪大道证券营业 | 5358.82 | 870.74 | | | 部 | | | | 买五 | 机构专用 | 4949.48 | 348.9 ...

康芝药业12月23日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 机构专用 | 6865.31 | 3104.25 | | 买二 | 机构专用 | 6230.60 | 2659.05 | | 买三 | 机构专用 | 5582.55 | 1359.67 | | 买四 | 机构专用 | 3646.63 | 120.29 | | 买五 | 中国银河证券股份有限公司北京中关村大街证券营业 | 3394.58 | 1204.24 | | | 部 | | | | 卖一 | 国泰海通证券股份有限公司成都北一环路证券营业部 | 36.08 | 9848.94 | | 卖二 | 国泰海通证券股份有限公司北京知春路证券营业部 | 220.69 | 8878.12 | | 卖三 | 开源证券股份有限公司西安西大街证券营业部 | 12.10 | 5678.61 | | 卖四 | 东方证券股份有限公司拉萨金珠西路证券营业部 | 0.00 | 4506.92 | | 卖五 | 机构专用 | 6865.31 | 3104.2 ...

Core Viewpoint - The company, Lianhuan Pharmaceutical (600513.SH), has received notification from the World Health Organization (WHO) that its active pharmaceutical ingredient, Levonorgestrel (APIMF484, WHO API-484), has passed the WHO prequalification (PQ) process and is now included in the procurement scope of international organizations and public institutions [1] Group 1 - The product has successfully passed the WHO prequalification site inspection [1] - As of the date of this announcement, the Drug Master File (DMF) review for the product has also been completed [1] - The product is now fully prequalified by the WHO [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received notification from the World Health Organization (WHO) that its raw material drug, Levonorgestrel, has passed the WHO prequalification, allowing it to be included in procurement by international organizations and public institutions [1] Group 1 - The company announced that its Levonorgestrel product is now recognized by the WHO, expanding its market potential [1] - The company's subsidiary, Changle Pharmaceutical, has received approval from the National Medical Products Administration for a supplemental application regarding Atropine Sulfate Injection, which includes the addition of a new specification of 1ml: 0.5mg [1] - The approval also pertains to the consistency evaluation of the quality and efficacy of the generic drug [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received notification from the World Health Organization (WHO) that its active pharmaceutical ingredient, Levonorgestrel, has passed the WHO prequalification process [1] Group 1: WHO Prequalification - The product Levonorgestrel has successfully undergone on-site inspection and the Drug Master File (DMF) review by the WHO, achieving full prequalification [1] - This prequalification is expected to enhance the company's credibility in the global market [1] Group 2: Financial Impact - The prequalification is not anticipated to have a significant impact on the company's current operating performance [1] - Future sales orders for the product remain uncertain, indicating potential variability in revenue generation [1]

从资金流向上来看，当日化学制药板块主力资金净流出7.77亿元，游资资金净流出8142.82万元，散户资 金净流入8.59亿元。化学制药板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，12月23日化学制药板块较上一交易日上涨0.41%，宏源药业领涨。当日上证指数报收于 3919.98，上涨0.07%。深证成指报收于13368.99，上涨0.27%。化学制药板块个股涨跌见下表： ...

圣达生物公告称，2025年7月，公司审议通过使用不超2.3亿元闲置募集资金进行现金管理的议案。10月 14日，公司用8000万元闲置募集资金购买了中国建设银行浙江分行单位人民币定制型结构性存款产品。 12月22日，该理财产品到期赎回，已收回本金8000万元及理财收益28.62万元，均归还至募集资金账 户，收益与预期无重大差异。 ...

Group 1: Chemical Sector Performance - The chemical raw materials index increased by 1.62%, while the chemical machinery index decreased by 0.96%, the chemical pharmaceuticals index fell by 1.69%, and the pesticide and fertilizer index rose by 4.21% [1] - The top five rising petrochemical products included folic acid up by 20%, battery-grade lithium carbonate up by 11.08%, nitric acid up by 10.43%, sulfur up by 9.95%, and petroleum coke up by 7.23% [1] - The top five declining petrochemical products were liquid chlorine down by 34%, butadiene down by 7.69%, 2,4-D down by 6.09%, trichloroethylene down by 6.00%, and SBS down by 5.90% [1] Group 2: Oil Sector Performance - The oil processing index rose by 1.39%, while the oil extraction index fell by 0.22%, and the oil trading index increased by 3.44% [1] - International crude oil prices continued to decline, with West Texas Intermediate crude oil futures settling at $56.66 per barrel, down 1.36% from December 12, and Brent crude oil futures settling at $60.47 per barrel, down 1.06% from December 12 [1] Group 3: Capital Market Performance of Listed Chemical Companies - The top five rising listed chemical companies included Sulihua Co., Ltd. up by 30.69%, Xinri Hengli up by 27.48%, Reborn Technology up by 23.25%, Ruihua Tai up by 20.93%, and Shenjian Co., Ltd. up by 20.50% [2] - The top five declining listed chemical companies were Huarong Chemical down by 20.01%, Enjie Co., Ltd. down by 18.36%, Weike Technology down by 13.15%, Jinbantai down by 12.83%, and Xingye Co., Ltd. down by 12.63% [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 HS387片是一款由公司自主研发的选择性KIF18A抑制剂，拟用于高级别浆液性卵巢癌、非小细胞肺癌 等晚期实体瘤治疗。该药品已经获得国家药品监督管理局颁发的《药物临床试验批准通知书》，详见公 司于2025年7月2日披露的《关于获得药物临床试验批准通知书的公告》（公告编号：临2025-37号）。 2025年11月，公司完成向美国FDA递交HS387片的临床试验申请，并于近日获得FDA批准。截至目前， 国内外有多款KIF18A抑制剂进入临床研发阶段，目前尚无药物上市。 近日，浙江海正药业股份有限公司（以下简称"公司"）收到美国食品药品监督管理局（以下简称"美国 FDA"）的通知，由公司申报的HS387片药品临床试验申请已获得美国FDA批准，可以在美国开展临床 试验。现就相关情况公告如下： 一、药品基本情况 药品名称：HS387片 IND编号：IND 178632 申请事项：新药临床试验申请 申请人：浙江海正药业股份有限公司 二、该药品研发及相关情况 董事会 二○二五年十二月二十三日 ...